We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp...
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNA Canada NewsWire TORONTO, le 26 avril 2024 TORONTO, le 26 avril 2024 /CNW/...
Canadian Investment Regulatory Organization Trade Resumption - MDNA Canada NewsWire TORONTO, April 26, 2024 TORONTO, April 26, 2024 /CNW/ - Trading resumes in: Company: Medicenna Therapeutics...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNA Canada NewsWire TORONTO, le 26 avril 2024 TORONTO, le 26 avril 2024 /CNW/...
Canadian Investment Regulatory Organization Trading Halt - MDNA Canada NewsWire TORONTO, April 26, 2024 TORONTO, April 26, 2024 /CNW/ - The following issues have been halted by CIRO: Company:...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp...
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.49 | -17.7536231884 | 2.76 | 2.76 | 2.25 | 144750 | 2.45825187 | CS |
4 | 0.59 | 35.119047619 | 1.68 | 2.89 | 1.5 | 139610 | 2.24830745 | CS |
12 | 1.2 | 112.14953271 | 1.07 | 2.89 | 1 | 163552 | 1.79893579 | CS |
26 | 1.77 | 354 | 0.5 | 2.89 | 0.38 | 106971 | 1.47188854 | CS |
52 | 1.37 | 152.222222222 | 0.9 | 2.89 | 0.215 | 83610 | 1.10183101 | CS |
156 | -1.88 | -45.3012048193 | 4.15 | 4.84 | 0.215 | 59245 | 1.6276715 | CS |
260 | 1.6 | 238.805970149 | 0.67 | 7.25 | 0.215 | 71850 | 2.72643754 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions